Organ-on-a-Chip Resources

How to effectively adopt and leverage Organ-on-a-chip

Explore seven key factors to guide your pharmaceutical teams in selecting an Organ‑on‑a‑chip (OOC) system that suits your specific needs. By understanding these elements, you can adopt and leverage Organ-on-a-chip technologies within your preclinical workflows more effectively.

A primary human Gut/Liver microphysiological system to estimate human oral bioavailability

We combine the primary Gut/Liver MPS with a mechanistic mathematical model to generate organ-specific pharmacokinetic parameters and estimate human oral bioavailability and its components

Accelerating DILI Prediction: A High-Throughput Liver-on-a-Chip Solution

Until now, there has been an inverse relationship between the high human-relevance required to predict human outcomes and throughput capacity. This has limited the application of Liver-on-a-chip, or Liver microphysiological systems (MPS), to smaller-scale investigative toxicity studies.

Get Ready for Regulatory Changes and the Future of NAMs

Join us for an insightful fireside chat between Chief Scientists from CN Bio, and LifeNet Health on how to get ready for regulatory changes in light of the recent FDA announcement.

Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies

Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins, and formulation design.

PhysioMimix® cross-species DILI CRS for enhanced IVIVE

Gain clarity, confidence, speed, and enhance your ethical responsibility by leveraging our cross-species Drug-induced liver injury assays (human, rat and dog) in your drug discovery or development workflow. Improve your in vitro to in vivo extrapolation (IVIVE) capabilities today via our DILI Contract Research Service.

CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI

Building Confidence in MPS for Regulatory Applications!

PhysioMimix Bioavailability assay kit: Human 18 brochure

Modernize your workflow with the only in vitro bioavailability assessment tool on the market. Elevate your workflow with our all-in-one Bioavailability assay kit containing everything you need to recreate our human in vitro Gut/Liver-on-a-chip model and Bioavailability assay in your laboratory.

PhysioMimix DILI assay kit: Human 24 brochure

Predict more complex, latent and immune-related hepatotoxicity in vitro. The PhysioMimix DILI assay kit contains everything you need to recreate our FDA-recognized assay in your own laboratory.

Harnessing Liver-on-a-chip models for drug safety

Webinar Series 8 Episode 2

Discover how to leverage human and animal Liver-on-a-chip (aka Liver microphysiological systems) in toxicology studies to enhance data translatability between preclinical testing and clinical applications.

Featuring industry experts from CN Bio and Bristol Myers Squibb.

Why the FDA animal testing phase-out for monoclonal antibodies?

In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal antibodies, followed by other drugs – signaling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing.

Microphysiological systems for mAbs development: how do they address animal limitations?

Part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs), and other drugs, in favor of human-relevant new approach methodologies (NAMs).